"A preliminary review by the Office of the Attorney General
revealed that Mylan Pharmaceuticals may have
inserted potentially anticompetitive terms into its
EpiPen sales contracts with numerous local school systems,"
Schneiderman's office said
in a statement.

The investigation stems from concerns that Mylan may have
blocked schools participating in the EpiPen4Schools
program from ordering EpiPen alternatives (such as the
Adrenaclick) from its competitors.

Mylan did not immediately respond to a request for comment about
the investigation, but the company previously
told Business Insider that there was a "a limited
purchase restriction, but such restriction no longer remains."

To fend off public outrage over the EpiPen's cost, the company
recently raised its copay-coupon system to cover $300 of people's
out-of-pocket cost. The compay has also said that it would
make an "authorized
generic" version of the EpiPen that would cost $300 for a
two-pack, half the list price of the branded drug. Mylan is
also facing
accusations that it overcharged Medicaid, and lawmakers have
been asking for
federal investigations into the price of the drug.